Risk formulas in calcium oxalate urolithiasis

World Journal of Urology

Volumn 15, Issue 3, 1997, Pages 176-185

  Tiselius, Hans Göran ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CALCIUM OXALATE; CITRIC ACID; MAGNESIUM;

BIOLOGICAL MODEL; CRYSTALLIZATION; HUMAN; METABOLISM; PROBABILITY; REVIEW; RISK ASSESSMENT; UROLITHIASIS;

CALCIUM; CALCIUM OXALATE; CITRIC ACID; CRYSTALLIZATION; HUMANS; MAGNESIUM; MODELS, BIOLOGICAL; PROBABILITY; RISK ASSESSMENT; URINARY CALCULI;

EID: 0030632644     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02201855     Document Type: Article

References (50)

1. Achilles W, Jockei U, Schaper A, Ulshöfer B, Riedmiller H (1994) Formation of urinary stones in vitro: growth of calcium oxalate on spherulites of calcium phosphate in gel. In: Ryall R, Bais R, Marshall VR, Rofe AM, Smith LH. Walker VR (eds) Urolithiasis, vol 2 Plenum Press, New York London, pp 161-165
2. Ahlstrand C, Tiselius HG (1981) Metabolic effects of bendroflumethiazide in patients with recurrent calcium oxalate stone disease. J Urol 126: 635-639
3. Ahlstrand C, Tiselius HG, Larsson L, Hellgren E (1984) Clinical experience with long-term bendroflumethiazide treatment in calcium oxalate stone formers. Br J Urol 56: 255-262
4. Asplin J, Mandel NS, Coe FL (1996) Evidence for calcium phosphate supersaturation in the loop of Henle. Am J Physiol 270: F604-613
5. Berg C, Larsson L, Tiselius HG (1992) The effects of a single evening dose of alkaline citrate on urine composition and calcium stone formation. J Urol 148: 979-985
6. Brundig P, Berg W, Naumann J, Hoppe H, Cumme GA. Achilles W, Schneider HJ (1980) Kalzium-Oxalate-Aktivitätsprodukte und diskriminanzanalytische Verrechnungen von Harnparametern als grundlage eines Kalzium-Oxalat-Screening-Programmes. Urologe A 19: 54-56
7. Daudon M, Labrunie M, Ivaldi A, Hennequin C, Lacour B, Jungers P (1996) A new crystallization risk index (CRI) for calcium oxalate (CaOx) stone-formers. In: Pak CYC, Resnick MI, Preminger GM (eds) Urolithiasis 1996. Millet. Dallas, pp 357-358
8. Di Silverio F, D'Angelo AR, Gallucci M, Seccareccia F, Menotti A (1996) Incidence and prediction of stone recurrence after lithotripsy in idiopathic calcium stone patients: a multivariate approach. Eur Urol 29: 41-46
9. Drach GW (1976) Contribution to therapeutic decisions of ratios, absolute values and other measures of calcium, magnesium, urate or oxalate balance in stone formers. J Urol 116' 338-340
10. Esen T. Akinci M, Tellaloglu S (1994) Stone formation risk index (SFRI): a possible prognostic factor governing the need for metaphylaxy. In: Ryall R, Bais R, Marshall VR, Rofe AM. Smith LH, Walker VR (eds) Urolithiasis, vol 2. Plenum Press. New York London
11. Evans RA. Forbes MA, Sutton RAL, Watson L (1967) Urinary excretion of calcium and magnesium in patients with calcium-containing stones. Lancet II: 958-961
12. Fellström B, Backman U. Danielson BG, Johansson G, Ljunghall S. Wikström B (1982) Urinary excretion of urate in renal calcium stone disease and in renal tubular acidification disturbances. J Urol 127: 589-592
13. Gambaro G. Cicerello E, Marzaro G, Marchini F, Piccoli A. Paleari C. Baggio B (1986) A critical evaluation of the urinary inhibiting activity in idiopathic calcium oxalate nephrolithiasis. Urol Int 41: 418-421
14. Györy AZ, Ashby R (1996) Calcium salt Urolithiasis: a radical new approach and its clinical application (abstract). J Endourol 10 [Suppl 1]: S55
15. Hauser W, Kunit G, Frick J (1992) Wertigkeit das KalziumZitrat-Quotienten bei Kalzium-Steinbildern. Z Urol Poster 1: 36
16. Hess B, Kok DJ (1996) Nucleation, growth and aggregation of stone-forming crystals. In: Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM (eds) Kidney stones. Medical and surgical management. Lippincott-Raven, Philadelphia New York, pp 3-32
17. Höbarth K, Hofbauer J, Szabo N (1994) Value of repeated analyses of 24-h urine in recurrent calcium Urolithiasis. Urology 44: 20-25
18. King JS Jr, O'Connor FJ Jr, Smith MJV, Grouse L (1968) The urinary calcium/magnesium ratio in calcigerous stone formers. Invest Urol 6: 60
19. Kok DJ Khan SR (1995) Chances for a free or fixed particle mechanism. In: Rao PN, Kavanagh JP, Tiselius HG (eds) Urolithiais consensus and controversies. Proceeding of the Fifth European Urolithiasis Symposium, Manchester, pp 431-432
20. Laerum E (1984) Recurrent Urolithiasis: a general-practice study of risk factors and clinical consequences. Scand J Urol Nephrol 18: 67-70
21. Lieske JC, Coe FL (1996) Urinary inhibitors in renal stone formation. In: Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM (eds) Kidney stones. Medical and surgical management. Lippincott-Raven, Philadelphia New York, pp 65-113
22. Ljunghall S, Waern U (1977) Urinary electrolytes in renal stone formers and healthy subjects. A population study of 60-yearold men. Scand J Urol Nephrol Suppl 41: 55-75
23. Luptâk J, Bek-Jensen H, Fornander AM, Höjgaard I, Nilsson MA, Tiselius HG (1994) Crystallization of calcium oxalate and calcium phosphate at supersaturation levels corresponding to those in different parts of the nephron. Scanning Microsc 8: 4762
24. Marangella M, Daniele PG, Ronzani M, Sonego S, Linari F (1985) Urine saturation with calcium salts in normal subjects and idiopathic calcium stone formers estimated by an improved computer model system. Urol Res 13: 189-193
25. Oreopoulos DG. Soyannwo MAO, McGeown MG (1968) Magnesium/calcium ratio in urine of patients with renal stones. Lancet II: 420-422
26. Parks JH, Coe FL (1986) A urinary calcium-citrate index for the evaluation of nephrolithiasis. Kidney Int 30: 85-90
27. Robert M, Boularan AM, Delbos O, Monnier L, Grasset D (1996) Evaluation of the risk of stone formation: Study on crystalluria in patients with recurrent calcium oxalate Urolithiasis. Eur Urol 29: 456-461
28. Robertson WG, Peacock M, Marshall RW, Marshall DH. Nordin BEC (1976) Saturation-inhibition index as a measure of the risk of calcium oxalate stone formation in the urinary tract. N Engl. J Med 294: 249-252
29. Robertson WG, Peacock M, Heyburn PJ, Marshall DH, Clark PB (1978) Risk factors in calcium stone disease of the urinary tract. Br J Urol 50: 449-454
30. Ryall RL, Marshall VR (1983) The value of the 24 h urine analysis in the assessment of stone formers attending a general hospital outpatient clinic. Br J Urol 55: 1-5
31. Ryall RL, Darroch JN. Marshall VR (1984) The evaluation of risk factors in male stone formers attending a general hospital out-patient clinic. Br J Urol 56: 116-121
32. Tiselius HG (1979) Relationship between the severity of renal stone disease and urine composition. Eur Urol 5: 322-327
33. Tiselius HG (1982) An improved method for the routine biochemical evaluation of patients with recurrent calcium oxalate stone disease. Clin Chim Acta 122: 409-418
34. Tiselius HG (1983) Different estimates of the risk of calcium oxalate crystallization in urine. Eur Urol 9: 231-234
35. Tiselius HG (1985) A simplified estimate of the ion-activity product of calcium phosphate in urine. Eur Urol 10: 191-195
36. Tiselius HG (1985) Measurement of the risk of calcium oxalate crystallization in urine. Urol Res 13: 297-300
37. Tiselius HG (1987) Measurement of the risk of calcium phosphate crystallization in urine. Urol Res 15: 79-81
38. Tiselius HG (1991) Aspects on estimation of the risk of calcium oxalate crystallization in urine. Eur Urol 47: 255-259
39. Tiselius HG (1994) Investigation of single and recurrent stone formers. Miner Electrolyte Metab 20: 321-327
40. Tiselius HG (1996) Solution chemistry of supersaturation. In: Coe FL. Favus MJ, Pak CYC, Parks JH, Preminger CM (eds) Kidney stones. Medical and surgical management. LippincottRaven. Philadelphia New York, pp 33-64
41. Tiselius HG, Larsson L (1980) Validity of biochemical findings in the evaluation of patients with urolithiasis. Eur Urol 6: CO94
42. Tiselius HG. Sandvall K (1990) How are urine composition and stone disease affected by therapeutic measures at an outpatient stone clinic? Eur Urol 17: 206-212
43. Tiselius HG, Almgârd LE, Larsson L. Sörbo B (1978) A biochemical basis for grouping of patients with urolithiasis. Eur Urol 4: 241-249
44. Tiselius HG. Berg C, Fornander AM, Nilsson MA (1993) Effects of citrate on the different phases of calcium oxalate crystallization. Scanning Microsc 7: 381-391
45. Tiselius HG, Bek-Jensen H, Fornander AM, Nilsson MA (1995) Crystallization properties in urine from calcium oxalate stone formers. J Urol 23: 215-221
46. Tiselius HG, Hojgaard I, Fornander AM, Nilsson MA (1996) Is calcium phosphate the natural promoter of calcium oxalate crystallization? In: Pak CYC, Resnick Ml. Preminger GM (eds) Urolithiasis 1996. Millet, Dallas, pp 238-239
47. Trinchieri A, Nespoli R, Rovera F. Curro A, Zanetti G (1996) Comparison between single renal stone formers and recurrent renal stone formers (abstract). Eur Urol 30 [Suppl 2]: 33
48. Wasserstein AG, Stolley PD, Soper KA, Goldfarb S, Maislin G. Agus Z (1987) Case-control study of risk factors for idiopathic calcium nephrolithiasis. Miner Electrolyte Metab 13: 85-95
49. Werness PG. Brown CM, Smith LH, Finlayson B (1985) Equil 2. A basic computer program for the calculation of urinary saturation. J Urol 134: 1242-1244
50. Yendt ER, Cohanim M (1973) 10 years experience with the use of thiazides in the prevention of kidney stones. Trans Am Clin Clim Assoc 85: 65-75